The interest in combining immunotherapy with PARP inhibitor in ovarian cancer is growing, owing to PARP inhibitors with the ability of synthetic lethality in cancer cells and their important roles in enhancing the efficiency of immunotherapy. Here, PARP1 is linked to ovarian carcinoma.